The effectiveness and tolerability of atropine eye drops for myopia control in non-Asian regions

Dovile Simonaviciute, Andrzej Grzybowski, Carla Lanca, Chi Pui Pang, Arvydas Gelzinis, Reda Zemaitiene

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)
28 Downloads (Pure)

Abstract

Myopia is the most common ocular disorder worldwide with an increasing prevalence over the past few decades. It is a refractive error associated with excessive growth of the eyeball. Individuals with myopia, especially high myopia, are prone to develop sight-threatening complications. Currently, atropine is the only drug that is used to slow myopia progression in clinical practice. However, there are still areas of uncertainty such as treatment strategy, optimal concentration when considering risk–benefit ratio and active treatment period. Since the prevalence of myopia is much higher in Asian countries, most of the research on myopia control has been conducted in Asia. Data on the efficacy and tolerability to atropine eye drops in the non-Asian population remains limited. In this review, we summarize the results of published clinical trials on the effectiveness and tolerability of atropine eye drops for myopia control in non-Asian regions. The efficacy was evaluated by the mean change in spherical equivalent (SE) or axial length (AL). The tolerability of atropine eye drops was analyzed based on patients complains and adverse events. The results of this review suggest that 0.01% atropine eye drops are effective in non-Asian regions achieving less side effects compared to 0.5% concentration.

Original languageEnglish
Article number2314
JournalJournal of Clinical Medicine
Volume12
Issue number6
DOIs
Publication statusPublished - Mar 2023

Keywords

  • atropine eye drops
  • myopia control
  • myopia progression
  • myopia treatment

Fingerprint

Dive into the research topics of 'The effectiveness and tolerability of atropine eye drops for myopia control in non-Asian regions'. Together they form a unique fingerprint.

Cite this